RNA Manufacturing Articles

  1. Suppressor tRNA Therapeutics: A New Frontier In Treating Genetic Disease 5/8/2026

    Suppressor tRNAs could unlock a scalable new way to treat genetic diseases caused by nonsense mutations, restoring full-length proteins across multiple indications.

  2. Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune Reset 5/4/2026

    In this Q&A, Michael Lam, Ph.D., explores how circular RNA and targeted delivery extend transient CAR expression to enable deep B-cell depletion and controllable immune reset.

  3. Bridging The Manufacturing Chemistries Between Drug Research And Development For Morpholino Oligos 4/29/2026

    Standardizing Morpholino chemistry could streamline development and FDA pathways, improving consistency, scalability, and delivery performance across antisense therapeutics.

  4. From Supporting Component to Strategic Driver: The Evolving Role of gRNA in CRISPR Therapeutics 4/21/2026

    Guide RNA is evolving from a simple targeting reagent into a complex, engineered molecule shaped by expanding CRISPR modalities, increasing length and modification demands, and tighter integration with manufacturability, analytical control, and regulatory expectations.

  5. A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis 4/15/2026

    Co-tethered transcription boosts mRNA yield and purity by organizing transcription machinery, reducing dsRNA impurities, and streamlining production for scalable RNA therapeutics.

  6. A New Approach To RNA Synthesis And Purification: Rethinking A Persistent Bottleneck 4/14/2026

    Photocleavable supports enable light-triggered RNA release, reducing reliance on chromatography and streamlining synthesis, scalability, and purity for complex RNA therapeutics.

  7. Oligos, mRNA, Or Gene Editing: Where Should You Bet? 4/13/2026

    Investing in RNA and gene editing requires balancing risk, timing, and scale — understanding how oligos, mRNA, and CRISPR each drive value across a converging biotech landscape.

  8. Beyond The Gold Standard(s): Modernizing Oligonucleotide Synthesis 4/13/2026

    A few weeks ago, I had the chance to sit down with OPT Congress speaker Phil Baran, Richard Lerner Chair Professor, Department of Chemistry, Scripps Research. Baran was slated to (and did) present a keynote on the innovations shaping the next generation of oligo synthesis. Here, I share the biggest takeaways I had from our conversation, touching on how he sees the science of oligo chemistry and manufacturing advancing in the near and far future. 

  9. The RNA Ties That Bind: 3 Takeaways From The OPT Congress 4/1/2026

    Here, I unpack three takeaways I had from the OPT Congress, each of which I’d argue are indicative of the interconnectedness across the genetic medicines field.

  10. Rethinking ATMP Assurance When Sterility Timelines, Reality Misalign 3/27/2026

    The compendial 14-day sterility testing window exposes product and patient to numerous risks, but settling on a rapid alternative also presents its own set of challenges.